48th week of 2008 patent applcation highlights part 36 |
Patent application number | Title | Published |
20080292575 | HAIR CONDITIONING COMPOSITION COMPRISING QUATERNIZED SILICONE POLYMER, GRAFTED SILICONE COPOLYOL, AND DIALKYL CATIONIC SURFACTANT - Disclosed is a hair conditioning composition comprising: (a) a quaternized silicone polymer; (b) a grafted silicone copolyol; (c) a cationic surfactant system comprising a dialkyl quaternized ammonium salt cationic surfactant; (d) a high melting point fatty compound; and (e) an aqueous carrier. The present invention can provide improved conditioning benefits such as smooth feel and reduced friction in conditioning compositions using dialkyl quaternized ammonium salt cationic surfactants. | 2008-11-27 |
20080292576 | METHOD FOR IDENTIFYING HAIR CONDITIONER-RESISTANT HAIR-BINDING PEPTIDES AND HAIR BENEFIT AGENTS THEREFROM - A method for identifying hair conditioner-resistant hair-binding peptides is described. The hair conditioner-resistant hair-binding peptides bind strongly to hair from a hair conditioner matrix and are stable therein. Peptide-based benefit agents, such as hair conditioners and hair colorants, based on the hair conditioner-resistant hair binding peptides are described. The peptide-based hair conditioners and hair colorants consist of a hair conditioner-resistant hair-binding peptide coupled to a hair conditioning agent or a coloring agent, either directly or through an optional spacer. Hair care and hair coloring product compositions comprising these peptide-based hair conditioners and colorants are also described. | 2008-11-27 |
20080292577 | Novel Ethylene Copolymers, Compositions Comprising Same and Preparation and Treatment Methods - The invention concerns novel ethylene copolymers comprising polyethylene glycol (meth)acrylate monomers, cationic monomers, and optionally amphoteric, anionic and/or hydrophilic nonionic monomers, neutralized by particular neutralizing agents. The invention also concerns composition in particular cosmetic or pharmaceutical comprising said copolymers, as well as methods for preparing said copolymers, and cosmetic treatment methods using same. | 2008-11-27 |
20080292578 | Sustained release air freshening device - This invention relates to a device that provides controlled release of a fragrant or deodorizing substance: the fragrant or deodorizing substance being solublized with an appropriate carrier solvent within a polymeric matrix. The layers function as protective barriers, semi-permeable membranes, fragrance reservoirs, and adhesives. The device is capable of delivering a fragrance at a controlled rate for a prolonged period of time through the gradual diffusion and release of fragrant material carried by a solvent from a reservoir system to the semi-permeable UV curable, oligomer composition acting a fragrance release regulator. Additionally, the UV curable, oligomeric composition that forms the reservoir and regulating layer can be engineered to be adhesive through cure inhibition. The method of cure inhibition can also be utilized to create internal areas of high and low cross link density to further control the release rate of a fragrance. | 2008-11-27 |
20080292579 | Polymer-Based Serum Albumin Substitute - This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers. | 2008-11-27 |
20080292580 | Treatment of Inflammatory Diseases - An aqueous solution or at least one polyether polyol in a fluid for administration to a mammal, such as a human being, wherein the at least one polyether polyol has a molecular weight of from 200 to 4000 and is dissolved in the aqueous fluid in a concentration of from 0.01 to 10 mg/ml, preferably from 1 to 10 mg/ml. | 2008-11-27 |
20080292581 | Interleukin-11 Fusion Proteins - The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or antiinflammatory properties, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases. | 2008-11-27 |
20080292582 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 2008-11-27 |
20080292583 | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione following autologous stem cell transplantation - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2008-11-27 |
20080292584 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE - Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, and adjusting administration to the patient of metaxalone or the substance to avoid an adverse event associated with metaxalone. In another embodiment, the method comprises informing a user that metaxalone ais metabolized by a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product. | 2008-11-27 |
20080292585 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom - Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of Cancer. | 2008-11-27 |
20080292586 | Method and Use of Interferon Compositions For the Treatment of Avian Influenza - The present invention provides methods and uses for an interferon composition in the treatment of avian influenza. Transmission of avian influenza virus H5N1 to humans has been shown to be highly pathogenic. The present invention provides for methods of treatment that provide a broad spectrum, first line defense against avian influenza infection in humans. The methods of the present invention can be further extended to treat strains of avian influenza viruses that have resulted from antigenic drift, this potentially resulting in avian influenza based virus which is highly pathogenic and transmissible between humans. | 2008-11-27 |
20080292587 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS - The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2008-11-27 |
20080292588 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES - The invention is directed to 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 2008-11-27 |
20080292589 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: | 2008-11-27 |
20080292590 | Soluble Receptors and Methods for Treating Autoimmune or Demyelinating Diseases - The present invention relates to novel therapeutic protein useful in the treatment of diseases, in particular in human subjects. The results of the inventor strongly support the use of soluble IL-18Rα in the treatment of diseases such as autoimmune or demyelinating disease, in particular Multiple Sclerosis (MS). Accordingly, the invention provides soluble IL-18Rα for use in the treatment of autoimmune or demyelinating disease, in particular MS. The invention also provides methods of treating, preventing or ameliorating the symptoms of autoimmune or demyelinating disease, in particular MS, in a subject, preferably a human subject, by administering a therapeutically effective amount of said soluble IL-18Rα to the subject. | 2008-11-27 |
20080292591 | Tumor mouse models using lentiviral vectors - This invention provides model systems for study of tumors. Model cells and model animals are prepared to mimic characteristics of natural clinical tumors. The tumor models can be contacted with putative modulators to screen for therapeutics and to help understand tumorigenic processes. Model animals can include model cells, closely correlated to the characteristics of clinical tumors, in an environment closely mimicking that of the tumors in patients. Thus, the animal models are highly representative for use in clinical and pharmacological studies. | 2008-11-27 |
20080292592 | Oncolytic Adenovirus Armed with Therapeutic Genes - The present invention involves compositions and methods for treating preventing cancer using compositions including replication competent adenovirus. The application competent adenovirus may or may not encode a therapeutic polynucleotide. | 2008-11-27 |
20080292593 | GENE THERAPY FOR SPINAL CORD DISORDERS - The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site. | 2008-11-27 |
20080292594 | MUTANT REOVIRUSES AND METHODS OF MAKING AND USING - Provided herein is a mutant reovirus (e.g., a genetically-engineered ISVP). Compositions including mutant reoviruses and methods of using such mutant reoviruses are also provided. | 2008-11-27 |
20080292595 | AAV vectors for gene delivery to the lung - Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue. | 2008-11-27 |
20080292596 | METHODS OF PRODUCING EDIBLE FUNGI CONTAINING ACTIVATED FOLATES AND NUTRITIONAL SUPPLEMENTS CONTAINING ACTIVATED FOLATES - Methods are described for producing reduced, methylated, biologically active forms of folate, including 5-methyltetrahydrofolate (i.e. 5-methyltetrahydropteroylglutamic acid), 5-formyltetrahydrofolate, 10-formyltetrahydrofolate and tetrahydrofolate. Edible mushroom-producing fungi are cultivated to enhance the uptake of pteroylmonoglutamate (synthetic folate) into edible portions of the plants. The mushroom-producing fungi reduce and methylate the pteroylmonoglutamates into activated folates. The cultivated mycelia or mushrooms of the mushroom-producing fungi are harvested, and may be consumed directly or processed into oral dosage formats (capsules, tablets, softgels, powders, gel packets, liquids, nutritional bars, beverages) for use as functional foods or nutritional supplements. | 2008-11-27 |
20080292597 | Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases - A neurological disease is treated by administering to a patient a therapeutically effective amount of a composition including human umbilical cord stem cells. The composition may include growth factors mixed with the stem cells immediately prior to being administered. A specific pre and post transplantation protocol provides optimal methods for obtaining favorable clinical results. | 2008-11-27 |
20080292598 | CHIMERIC TRANSPLANT - Compositions comprising amniotic fluid stem cells which are derived from non-identical donor sources. Donors may be non-identical siblings, non-identical twins, and/or donors which are unrelated by a familial relationship. Also disclosed are methods for making such amniotic stem cell compositions, and methods for their use, such as therapeutic stem cell transplantation. | 2008-11-27 |
20080292599 | Chondrogenic Compositions and Methods of Use - The invention provides a method of treatment joint and disk disease comprising administering to the subject in need thereof a novel composition comprising a substantially purified plurality of cells enhanced with at least one bioactive factor capable of causing at least a portion of the plurality of cells to express an increased amount of at least one chondrogenic marker. | 2008-11-27 |
20080292600 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE - This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient. | 2008-11-27 |
20080292601 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH IL-10 EXPRESSING CELLS - This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient. | 2008-11-27 |
20080292602 | T Cell Receptors Which Specifically Bind to Vygfvracl-Hla-A24 - The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting the complex. | 2008-11-27 |
20080292603 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES USING GENE THERAPY - Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes. | 2008-11-27 |
20080292604 | Canine probiotic lactobacilli - According to the invention there is provided a strain of lactic acid bacteria of the genus | 2008-11-27 |
20080292605 | Materials for stimulation of hematopoiesis by ex vivo activated cells - A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from a plastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 2008-11-27 |
20080292606 | Pharmaceutical Oral Dosage Form Comprising a Non-Steroidal Anti-Inflammatory Drug, and Having Good Palatability - Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamin B6 and mixtures thereof. | 2008-11-27 |
20080292607 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease - This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate and/or oxaloacetate, fruit extracts and anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains substances that should attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O | 2008-11-27 |
20080292608 | Compounds and Compositions as Ppar Modulators - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families. | 2008-11-27 |
20080292609 | Use of Arginase in Combination with 5FU and Other Compounds for Treatment of Human Malignancies - The present invention provides a method for treating cancer in a human patient by reducing the physiological arginine levels to below 10 μM in combination with administering an anti-neoplastic compound. The present invention also provides a pharmaceutical composition comprising an arginine reducing compound, such as pegylated human arginase I, and an anti-neoplastic compound, such as | 2008-11-27 |
20080292610 | Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders - A medicament containing enzymes from ciliates selected from the group consisting of hydrolases, lipases, proteases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases. | 2008-11-27 |
20080292611 | NOVEL METHODS OF TREATMENT AND DELIVERY MODES - The invention relates to a novel method of administration, and device employed in the method, for administering a treatment species to the lungs of a recipient patient. The method involves introducing the device of the invention to the venous system of the patient, the size of the treatment species being such that, upon introduction to the venous system of the patient, the device will impact in a region of a lung capillary of the patient. The treatment species gains access to the lung and/or lung epithelia due to proteases associated with the treatments species. The application of the method to the treatment of cystic fibrosis is also claimed. | 2008-11-27 |
20080292612 | COMPOSITION CONTAINING SEVERAL BOTULIC TOXINS - The invention concerns a composition including at least one botulinum neurotoxin type A1, and one botulinum neurotoxin type A the amino acid sequence of which as at least 5% difference with the amino acid sequence of botulinum neurotoxin type A1. | 2008-11-27 |
20080292613 | Food Supplement Based on Group B Vitamins, Trace Elements and -3 and/or 6- Fatty Acids and Use of This Food Supplement in the Simultaneous Treatment of Localized Cellulite and Slackening of the Skin - The present invention relates to the use of a combination of group B vitamins, trace element(s), at least one oil comprising essential Ω-3 and/or Ω-6 fatty acids and an excipient suitable for oral administration, for use in the simultaneous treatment of excess weight and slackening of the skin localized in the same area. The invention also relates to a corresponding food supplement. | 2008-11-27 |
20080292614 | DNA sequences for human angiogenesis genes - Novel nucleic acid sequences and encoded polypeptides involved in the process of angiogenesis are provided. In particular, provided are a BNO69 nucleic acid of SEQ ID NO: 1 and a BNO69 polypeptide of SEQ ID NO: 115. Methods are provided for treating subjects having pathologies associated with angiogenesis and for the screening of drugs for pro- or anti-angiogenic activity. | 2008-11-27 |
20080292615 | DIAGNOSIS AND TREATMENT OF DISEASE - We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual. Methods of making medicaments and methods of treatment and/or prophylaxis are also disclosed. | 2008-11-27 |
20080292616 | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same - Disclosed are topical compositions comprising at least one histone deacetylase (HDAC) inhibitor (HDI) and a carrier comprising petrolatum. Methods for using such compositions to treat or inhibit cancer and various skin diseases are also disclosed. | 2008-11-27 |
20080292617 | ANTIBODY AGAINST A PEPTIDE DERIVED FROM HUMAN MUTANT LAMIN A PROTEIN AND USES THEREOF - Nearly all subjects affected with Hutchinson Gilford progeria syndrome (HGPS) carry mutation LMNA G608G (GGC>GGT), within exon 11 of LMNA activating a splicing donor site which leads to a deletion of 50 amino acids at the carboxyl-terminal of prelamin A. The invention provides an isolated peptide of sequence GAQSPQNC. The lamin A G608G polypeptide comprises the GAQSPQNC peptide. The invention provides monoclonal and polyclonal antibodies, which specifically recognize GAQSPQNC peptide, and any polypeptide which comprises GAQSPQNC. The invention provides methods, which use the inventive antibodies to detect biological conditions associated with lamin A G608G; and to identify agents which inhibit expression or localization of lamin A G608G. | 2008-11-27 |
20080292618 | INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY - Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway. | 2008-11-27 |
20080292619 | Pharmaceutical Composition Containing Meltrin Antagonist - Mainly concerning the pharmaceutical field, it is intended to exert an inhibitory effect on the function of meltrin α of promoting the differentiation of adipocytes by preparing a compound serving as an antagonist to meltrin α (for example, an antisense inhibiting the expression of a meltrin α gene or an anti-meltrin α antibody capable of inhibiting the physiological activity of meltrin α) and administering the same. By employing such a meltrin α antagonist as described above as the active ingredient, it becomes possible to provide a preventive/remedy which is efficacious against fatness, obesity or various diseases caused by obesity or relating thereto such as diabetes. | 2008-11-27 |
20080292620 | PRLR-Specific Antibody and Uses Thereof - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 2008-11-27 |
20080292621 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2008-11-27 |
20080292622 | METHODS OF EVALUATING PATIENTS - Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. | 2008-11-27 |
20080292623 | MAMMALIAN CELL MEMBRANE PROTEINS; RELATED REAGENTS - The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use. | 2008-11-27 |
20080292624 | Method of detecting and treating tuberous sclerosis complex associated disorders - Disclosed are methods of detecting and treating tuberous sclerosis complex associated disorders. Also disclosed are methods of identifying agents for treating tuberous sclerosis complex associated disorders. | 2008-11-27 |
20080292625 | PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY - The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody. | 2008-11-27 |
20080292626 | KINESIN INHIBITORS - This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder. | 2008-11-27 |
20080292627 | Compositions and Methods for Treating Mood and Anxiety Disorders - The invention relates method of disrupting the interface between Gsα and tubulin. The disruption of this interaction is a mechanism for treatment of mood and anxiety disorders and this interaction may be used to screen for and design therapeutics for mood and anxiety disorders. | 2008-11-27 |
20080292628 | Chimeric Protein - A fusion protein containing a first segment that is located at the amino terminus of the fusion protein and specifically binds to and neutralizes a first cytokine or growth factor; and a second segment that is located at the carboxyl terminus of the fusion protein and specifically binds to a second cytokine receptor which is often rich at disease sites such as IL-1 receptor-rich inflammatory site. In addition, the said second segment is usually the receptor antagonist such as IL-1 receptor antagonist and its functional equivalent analogues. Also disclosed are nucleic acids encoding the fusion protein, vectors and host cells having the nucleic acids, and related composition and methods to target inflammatory diseases and indications co-existed with inflammation. | 2008-11-27 |
20080292629 | System Clock Generation Circuit - A system clock signal generator circuit comprising a first PLL circuit that is frequency and phase locked to a wobble signal; a frequency and phase comparator for comprising a first output signal from the first PLL circuit with a system clock signal as frequency divided by M and for outputting a second output signal based on the differences in frequency and in phase; a PLL filter for providing a predetermined cutoff to the second output signal to output a third output signal; a pulse width modulating circuit for generating a pulse wave, the carrier frequency of which is a second reference clock signal, and for outputting a fourth output signal obtained by modulating the pulse width of the pulse wave by the third output signal; a low pass filter for smoothing the fourth output signal to output a fifth output signal; a VCO circuit the control voltage of which is the fifth output signal; a first frequency divider circuit for frequency dividing an output signal of the VCO circuit by N to output a system clock signal; and a second frequency divider circuit for frequency dividing, by M, and feeding the system clock signal back to the frequency and phase comparator. | 2008-11-27 |
20080292630 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2008-11-27 |
20080292631 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2008-11-27 |
20080292632 | Irta2 Antibodies and Methods of Use - Antibodies that specifically bind the extracellular domain of IRTA2 are disclosed herein. In one embodiment, these antibodies do not specifically bind IRTA1, IRTA3, IRTA4, or IRTA5. In one example, the antibodies are humanized antibodies. The antibodies can be conjugated to effector molecules, including detectable labels, radionucleotides, toxins and chemotherapeutic agents. The antibodies that specifically bind IRTA2 are of use to detect B cell malignancies, such as hairy cell leukemia and non-Hodgkin's lymphoma. These antibodies that specifically bind IRTA2 are also of use to treat B cell malignancies that express IRTA2, such as hairy cell leukemia and non-Hodgkin's lymphoma. | 2008-11-27 |
20080292633 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer. | 2008-11-27 |
20080292634 | Nontypable Haemophilus Infuenzae Virulence Factors - The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of | 2008-11-27 |
20080292635 | Allergenic latex protein - The present invention relates to a protein found in natural rubber that can induce an allergic reaction in persons who have been sensitised to it. The invention provides for the process of isolating and purifying the protein and describes the characteristics of the protein, including its molecular weight, isoelectric point, amino acid sequence and allergenicity. The invention also describes the isolation and cloning a the DNA that encodes the protein. The production of the recombinant version of the protein using a protein expression vector is described. | 2008-11-27 |
20080292636 | Chemokine panec-2 polynuleotides, polypeptides, antibodies and methods of making and using them - The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein. | 2008-11-27 |
20080292637 | Therapeutic Uses of A3 Adenosine Receptor Antibodies - The present invention concerns the use of an anti-A3 adenosine receptor (A3AR) immunoglobulin-based molecule for the preparation of a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3 adenosine receptor. Further provided by the invention is a method of treating a pathological condition associated with a high level of expression of A3 adenosine receptor in a subject, the method comprising administering to said subject an amount of the anti-A3AR immunoglobulin-based molecule, the amount being effective to treat or prevent said pathological condition. Finally, the present invention provides a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3AR comprising a physiologically acceptable carrier and the anti A3AR immunoglobulin-based molecule. | 2008-11-27 |
20080292638 | Tgf-Beta Binding Antibodies - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal. | 2008-11-27 |
20080292639 | Humanized Anti-Amyloid Antibody - Compositions for treating neurodegenerative or amyloidgenic disorders such as Alzheimer's disease (AD) are provided. More particularly, humanized anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided. | 2008-11-27 |
20080292640 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2008-11-27 |
20080292641 | Antigenic GM-CSF peptides and antibodies to GM-CSF - Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease. | 2008-11-27 |
20080292642 | Crystalline anti-human IL-12 antibodies - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. | 2008-11-27 |
20080292643 | LEUKOCYTE INACTIVATION MODULE - The present invention provides a module for reducing the activity of leukocytes which comprises a carrier and a ligand that is linked to the carrier and is suitable for interacting with a leukocyte receptor. Furthermore, the present invention provides a process for reducing the activity of leukocytes using said module. The advantage of the present invention is that after binding the activated leukocytes in the leukocyte inactivation module (LIM), the damaging effect of the cells is inhibited within minutes. | 2008-11-27 |
20080292644 | Compositions and methods for identifying response targets and treating flavivirus infection responses - Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-α is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-α secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%. | 2008-11-27 |
20080292645 | Antibody or Antibody Fragment Coupled with an Immunogenic Agent - An immunogenic conjugate includes a target cell-specific circulating molecule and at least one immunogenic agent, the immunogenic agent being coupled by any appropriate means with the circulating molecule. Also described is a method for preparing the immunogenic conjugate and its use for treating cancers or autoimmune diseases. | 2008-11-27 |
20080292646 | RECOMBINANT FUSION PROTEIN AND POLYNUCLEOTIDE CONSTRUCT FOR IMMUNOTOXIN PRODUCTION - The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of | 2008-11-27 |
20080292647 | MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS - The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma. | 2008-11-27 |
20080292648 | SYNTHETIC AGONISTS OF TLR9 - The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles. | 2008-11-27 |
20080292649 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING OF CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises
| 2008-11-27 |
20080292650 | THERAPEUTIC AND DIAGNOSTIC PEPTIDES - This invention generally relates to peptides useful for medical diagnosis and treatment of pathogenic disorders. More specifically, the invention relates to immunostimulatory peptides which can stimulate the production of therapeutically beneficial cytokines and, in combination with antibodies against human pathogens such as the immunodeficiency virus (HIV), inhibit replication of such pathogens. The peptides interact synergistically with pathogen-directed antibodies without producing or sustaining serious side-effects such as inflammation, and provide the potential for treatment modalities that are non-specific with respect to pathogen and cell type. Therefore, the peptides of the present invention have wide applicability with respect to medical treatment of pathogen-mediated infections, and the potential to enhance well-being. | 2008-11-27 |
20080292651 | Skin firming and lifting compositions and methods of use - Disclosed is a composition comprising a combination of: | 2008-11-27 |
20080292652 | Virus-Like Particles Comprising a Fusion Protein of the Coat Protein of Ap205 and an Antigenic Polypeptide - The present invention is in the fields of medicine, immunology, virology and molecular biology. The present invention provides a composition comprising a modified virus-like (VLP) particle derived from RNA bacteriophage AP205. The invention also provides a process for producing the aforementioned VLP. The modified VLP disclosed in the present invention is useful in the production of compositions for inducing immune responses for the prevention or treatment of diseases, disorders including infectious diseases, allergies, cancers and drug addiction. Moreover, the modified VLP disclosed in the present invention is, in particular, useful to efficiently induce self-specific immune responses, in particular antibody responses. | 2008-11-27 |
20080292653 | Live attenuated antigenically marked classical swine fever virus - Classical swine fever virus is a world-wide distributed highly-contagious disease affecting swine. The two main strategies for diseases control are prophylactic vaccination and non-vaccination stamping out policies. Marker vaccines are a promising strategy. Here we report the rational development of a doubly antigenic marker CSFV experimental live attenuated candidate strain vaccine (Flag/T4 virus). Flag/T virus (Flag/T4v) is based in the combination of two Brescia derived recombinant attenuated viruses: RB-C22 and T4. RB-C22v contains a 19mer insertion in the structural glycoprotein E1, while T4v posses mutated CSFV amino acid residues 830 to 834 in the structural glycoprotein E2, deleting the highly conserved epitope recognized by monoclonal antibody (mAb) WH303. Flag/T4 virus contains a positive foreign antigenic marker, due to the insertion of the highly antigenic epitope Flag in the 19mer insertion of E1, as well as a negative antigenic marker, the lack of reactivity with mAb WH303. Immunized with Flag/T4v induced a complete protection against the challenge with virulent strain Brescia both at 3 and 28 days post infection when nasally administered and since the second day post infection when intramuscularly administered. These results constitute an example of rational design of a CSFV antigenically marked LAV. | 2008-11-27 |
20080292654 | Human Bocavirus and Methods of Diagnosis and Treatment - Human parvovirus, genus Bocavirus, associated with respiratory tract infections in children. Nucleic acid and polypeptide sequences of the virus. Methods and products for diagnosing presence of bocavirus in a sample using nucleic acid probes or primers, or specific binding members such as antibodies. Methods and products for diagnosing past or present infection of bocavirus in an individual e.g. by serology testing. Viral nucleic acid, polypeptide and/or viral particles for generating immune response in an individual, including vaccine compositions. | 2008-11-27 |
20080292655 | ENHANCEMENT OF THE IMMUNE RESPONSE FOR VACCINE AND GENE THERAPY APPLICATIONS - Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells. | 2008-11-27 |
20080292656 | Combination of a Bacterial Cell and a Biologically Active Agent - The present invention is related to a combination comprising a first constituent and a second constituent, wherein the first constituent is a bacterial cell which comprises at least one recombinant nucleic acid molecule encoding a phagolysosomal escape peptide or polypeptide; and wherein the second constituent is a biologically active agent. In certain embodiments, the combination is of use as a vaccine to induce an immune response in a mammal. | 2008-11-27 |
20080292657 | PRIMATE T-LYMPHOTROPIC VIRUSES - Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses. | 2008-11-27 |
20080292658 | Defective Influenza Virus Particles - The invention relates to the field of influenza virus and the vaccination against flu. The invention provides a conditionally defective influenza virus particle having seven different influenza nucleic acid segments. The invention also provides a conditionally defective influenza virus particle lacking an influenza nucleic acid segment selected from the group of segments essentially encoding acidic polymerase (PA), the basic polymerase 1 (PB1) and the basic polymerase 2 (PB2). In particular, the invention provides defective influenza virus particles having seven different influenza nucleic acid segments and lacking an influenza nucleic acid segment essentially encoding acidic polymerase. Furthermore, the invention provides use of a composition comprising a defective influenza virus particle according to the invention for the production of a pharmaceutical composition directed at generating immunological protection against infection of a subject with an influenza virus, and provides a method for generating immunological protection against infection of a subject with an influenza virus comprising providing a subject in need thereof with a composition comprising such defective influenza virus particle. | 2008-11-27 |
20080292659 | Prime Boost Vaccine for the Protection of Equines Against Equine Influenza - The present invention is concerned with vaccinating equines against the equine influenza virus (EIV). | 2008-11-27 |
20080292660 | Hexavalent Bovine Rotavirus Reassortant Composition Designed for Use in Developing Countries - The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided. | 2008-11-27 |
20080292661 | Use of Botulinum Toxin for the Preparation of a Medicament for the Treatment of Lithiasis of Salivary Gland, Gall Bladder, Kidney, or Pancreas - The invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat a gland, organ or duct obstructed by a naturally formed stone. This method can be applied notably for salivary gland, gall bladder, kidney or pancreas stones. | 2008-11-27 |
20080292662 | Vaccine Comprising Recombinant Clpp Protein of Streptococcus Pneumoniae - This invention is about vaccine comprising recombinant CLPP protein of | 2008-11-27 |
20080292663 | ADJUVANT COMPOSITIONS AND METHODS FOR DELIVERING VACCINES - An adjuvant composition is provided that is comprised of a calcium compound, lecithin, and an acrylic polymer. Pharmaceutical compositions are provided which include an antigen and the adjuvant. Methods are provided for stimulating an immune response in a human or animal subject by administering a composition comprising an antigen and the adjuvant composition to human or animal subjects. | 2008-11-27 |
20080292664 | Hydrogels and Hyaluronic Acid and Alpha, Beta-Polyaspartyl-Hydrazide and Their Biomedical and Pharmaceutical Uses - Compositions and products based on the chemical crosslinking of hyaluronic acid with a polyfunctional polymer having a protein-like structure, bearing hydrazido pendent groups along the polymeric chain. The polymer is preferably, alpha-beta-polyaspartylhydrazide, a biocompatible macromolecule. The materials obtained after crosslinking, specifically hydrogels, undergo a reduced chemical and enzymatic degradation, unlike the starting hyaluronic acid, and they can be used to prepare systems for applications in the biomedical and pharmaceutical field. | 2008-11-27 |
20080292665 | Simple mechanical procedure and product for deterring substance abuse - Simple mechanical methods improve safety of a substance that is at risk for abuse. The substance is made in a specified form that tends to deter conversion to powder: and in this form commercially distributed, e.g. wholesale or retail. Preferably that form is enclosed in a harmless container. Preferably the method also includes putting the substance into or onto a harmless carrier. Preferably the carrier does not dissolve in. It may e oil or solid—for example paper or similarly thin medium, or a sponge or other medium that has generally course cellular structure. | 2008-11-27 |
20080292666 | Preparation for Preventing or Treating Calcium Deficiency Conditions In Mammals - An essentially dry powdered preparation containing a calcium source for the prevention and treatment of calcium deficiency conditions in mammals, e.g. dairy cows, is enclosed in a substantially water soluble, dispersible or disintegrable casing mainly composed of a cellulose material such as e.g. paperboard, cardboard, millboard, or pasteboard, or a gelatinized starch material. The calcium source is preferably a mixture of calcium chloride and calcium propionate enclosed in a cylindrical paperboard or cardboard tube or a gelatinized starch shell closed at both ends, which is administered to an animal with a bolus or bullet gun. The administration is safe and clean and the powdered mixture is quickly released in the stomach or rumen without causing erosion, irritation or inflammation of the mucosa. | 2008-11-27 |
20080292667 | Nonwoven Nanofibrous Membranes of Silk Fibroin for Guided Bone Tissue Regeneration and Their Preparation Method - The present invention relates to a membrane for guided bone tissue regeneration and, more particularly, to a membrane for guided bone tissue regeneration having a structure that silk fibroin nanofibers obtained by removing sericin from silk fibers are formed as a nonwoven, and a manufacturing method thereof. | 2008-11-27 |
20080292668 | Water-Free Cosmetic Preparation - A water-free composition, in particular a cosmetic composition, in the form of a pencil with a cast or extruded lead or a workable paste which is suitable for cosmetic uses, in particular in the field of decorative cosmetics, for coloring, improving the appearance of and caring for keratinic materials such as for example the skin, semi-mucous membranes and mucous membranes, eyelashes, eyebrows and the hair. That preparation includes a specifically matched combination of water-soluble and lipid-soluble active substances in the form of a so-called “active substance cocktail”. The production and use of that composition are also described. | 2008-11-27 |
20080292669 | Foamed Substrate and Method for Making Same - The present invention provides a foamed and/or aerated substrate for transmucosal and/or transdermal applications. The foamed and/or aerated substrate may be in the form of a film, sheet, strip or wafer. The foamed and/or aerated substrate is suitable for use in applications such as, for example, adhesive denture liners, tooth whitening, and smoking control/cessation. The foamed and/or aerated substrate is polymeric in nature and comprises one or more polymers and one or more foaming agents. Additionally, the foamed and/or aerated substrate may include, but not limited to, one or more plasticizers, hydrophobic barrier agents, tooth whitening agents, antioxidants, preservatives, super-disintegrants or absorbents, flavorants, deodorants, breath freshening agents, colorants, surfactants, film modifiers, cross-linking agents, antimicrobial agents, control release agents, other therapeutic agents, or any combinations thereof. | 2008-11-27 |
20080292670 | Adhesive and plaster - An adhesive comprising a base with tackiness, an oil and ketoprofen, wherein the adhesive contains no L-menthol, the base is composed at least of a tacky composition comprising an elastomer and a tackifier and/or a tacky polymer containing an unsaturated monomer with a total of 5 or more carbon atoms as the monomer unit, the oil is an oil that is compatible with the tacky composition and the tacky polymer, and the oil content is 150-175 parts by weight with respect to 100 parts by weight as the total of the tacky composition and the tacky polymer. | 2008-11-27 |
20080292671 | Antimicrobial Medicotechnical Product, Process for its Preparation and Use - The invention relates to a medicotechnical product having an antimicrobial finish of a complex material of metal nanoparticles and macromolecules, the macromolecules being formed at least partially from a polyamino acid. | 2008-11-27 |
20080292672 | Active Compound-Containing Solid Moulded Bodies for External Use Against Parasites on Animals - The present invention relates to active compound-containing moulded bodies for external use against parasites on animals. | 2008-11-27 |
20080292673 | Bioactive agrichemical compositions and use therreof - Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations. | 2008-11-27 |
20080292674 | Bioactive agrichemical compositions and use thereof - Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations. | 2008-11-27 |